Bone marrow inhibition induced by azathioprine in a patient without mutation in the thiopurine S-methyltransferase pathogenic site:A case report
作者机构：College of Biomedical EngineeringTaiyuan University of TechnologyTaiyuan 030012Shanxi ProvinceChina Department of NephrologyThe Affiliated People's Hospital of Shanxi Medical UniversityTaiyuan 030032Shanxi ProvinceChina Department of GastroenterologyShanxi Bethune HospitalTaiyuan 030012Shanxi ProvinceChina
出 版 物：《World Journal of Clinical Cases》 (世界临床病例杂志)
年 卷 期：2021年第9卷第17期
页 面：4230-4237页
核心收录：
学科分类：1007[医学-药学(可授医学、理学学位)] 1006[医学-中西医结合] 100706[医学-药理学] 100602[医学-中西医结合临床] 10[医学]
主 题：Azathioprine Thiopurine S-methyltransferase Bone marrow inhibition Lupus nephritis Case report
摘 要：BACKGROUND Azathioprine(AZA)and its close analog 6-mercaptopurine are thiopurines widely used in the treatment of patients with cancer,organ transplantation,and autoimmune or inflammatory diseases,including systemic lupus *** marrow inhibition is a common side effect of AZA,and severe bone marrow inhibition is related to decreased thiopurine S-methyltransferase(TPMT)*** SUMMARY We herein report a patient with proliferative lupus nephritis who was using AZA for maintenance therapy,had no common TPMT pathogenic site mutations,and exhibited severe bone marrow inhibition on the 15th day after oral *** This report alerts physicians to the fact that even though the TPMT gene has no common pathogenic site mutation,severe myelosuppression may also occur.
维普期刊数据库